Clinical trial · Observational
NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
NCT03194971CI-TRIAL-00106732completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumor samples from patients treated with TTFields at initial diagnosis. | Other | — | UNRESOLVED |
| Tumor samples from patients treated with TTFields at tumor recurrence. | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TTField at Recurrence
- interventionNames
- Device: Tumor samples from patients treated with TTFields at tumor recurrence.
- label
- TTField at New Diagnosis
- interventionNames
- Other: Tumor samples from patients treated with TTFields at initial diagnosis.
Primary outcomes (3)
- measure
- Number of mitotically active cells
- timeFrame
- At baseline
- description
- Tissue samples will be obtained at autopsy and stained for KI-67. Slides will then be digitized, and the number of active cells will be counted computationally.
- measure
- Number of mitotically inactive cells
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy. * Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy. Exclusion Criteria: * TTField compliance \< 75%. * Any contraindication to Optune TTField treatment. * Initial brain tumor diagnosis \< WHO grade IV. * Duration of TTField therapy \< 3 months.
References
Publications (0)
Data not yet available
No reference posted for this study.